If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 81 - 90 of 279
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia
Objective
This project is being done to see if a safe dose of JNJ-75276617 can be identified for treating participants with acute leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Protocol No
JNJ-75276617ALE1001
Phase 1/1b, Open-Label, Dose-Escalation, Dose-Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) a
Objective
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL B-cell
Protocol No
PRECISION-PBCAR0191-01
Categories
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients with Vestibular Schwannomas
Objective
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas (VS PREHAB)
Protocol No
IIT-HARRIS-PREHAB-VS
Categories
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer with High-Risk of Cancer Recurrence (PROTECT-PANC)
Objective
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence (PROTECT-PANC)
Protocol No
IIT-KAMGAR-PROTECT-PANC
Categories
The Role of Nodal Radiation Therapy in Sentinel Lymph Node Positive Melanoma
Objective
The role of nodal radiation therapy in sentinel lymph node positive melanoma
Protocol No
MDA-2020-0148
Categories
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Objective
Prospective, Observational Study of Participants at Risk for CGVHD
Protocol No
INCYTE-MA-GVHD-401-THRIVE
Categories
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: A Phase II Clinical Study
Objective
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. A sample of the vaginal fluid pool will be collected via a standard tampon from each study participant prior to any clinical exams or procedures. A peripheral blood sample will be collected from each study participant prior to any clinical exams or procedures.
Protocol No
MAYO-ECHO-STUDY
Categories
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Objective
A Phase 2 Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis
Protocol No
NMDP-CIBMTR-OPTIMIZE
Categories
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer
Objective
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104